How CEO Exit At Bausch + Lomb Stock Has Changed Its Investment Story

• Bausch + Lomb announced that CEO Brent Saunders left the business and its board on October 12, 2026, with board chair Thomas J. Appio stepping in as interim chief executive while continuing to lead Bausch Health.
• The leadership change arrives while Bausch + Lomb is working through weaker earnings per share, pressured free cash flow margins and subpar return on invested capital, which keeps execution quality in sharp focus.
• We will now assess how Bausch + Lomb's interim CEO appointment could influence the existing investment narrative around profitability and execution.

Scan how other eye care and healthcare stocks are handling leadership shifts and profitability pressure with a curated list of list of solid balance sheet and fundamentals (25 results)

Bausch + Lomb Investment Narrative Recap

To stay comfortable as a shareholder in Bausch + Lomb, you need to believe the eye health portfolio and Vision 27 cost program can eventually translate forecast revenue growth and improving margins into sustainable earnings, despite current losses and weaker free cash flow. The CEO change looks contained, since the board states Brent Saunders did not leave because of disagreements over how the business is run.

The more pressing near term swing factor is execution on profitability, given earnings per share pressure and return on invested capital sitting below typical healthcare hurdles. Leadership transition could slow decision making on spending and portfolio priorities, which keeps integration with Bausch Health and any further board turnover as key risks to watch.

The most relevant recent announcement in the context of this leadership shuffle is Bausch + Lomb’s update on BL1243, the oral tonabersat program for dry age related macular degeneration. Management gained clarity from the FDA on the clinical path, with an initial study focused on how the drug behaves in the body and its safety profile.

You should see this in the context of catalysts and execution rather than near term earnings. BL1243 sits in early development, with a Phase 2 trial planned for 2027, so the economic impact is distant while costs land sooner. The CEO handover puts extra attention on how tightly the company manages R&D spending and timelines for this program alongside existing dry eye and retina franchises.

Bausch + Lomb's current analyst story centers on projected revenue of US$6.4b and earnings of US$325.4m by 2029, based on 6.2% yearly revenue growth and an earnings change of roughly US$496m from a loss of US$171.0m today.

Uncover why Bausch + Lomb's fair value indicates an 18% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

Some of the most optimistic analysts focus on Bausch + Lomb’s Vision 27 cost program as a major catalyst, expecting profit margins to reach 8.0% and earnings of about US$525.9m by 2029, compared with consensus at US$325.4m. That confidence predates the CEO exit, so you may want to see how opinions shift as the leadership change sinks in.

Explore 4 other Bausch + Lomb fair value estimates, including one that suggests there could be as much as 138% upside from the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own research and judgment.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Bausch + Lomb. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, which makes it easier to evaluate Bausch + Lomb's overall financial health at a glance.

Looking for more Bausch + Lomb style investment ideas?

If you want to put the Bausch + Lomb storyline in context, compare it with other companies that match clear financial filters inside the Simply Wall St Screener.

• For investors who want quality at a reasonable entry point, start with a curated mix of underpriced opportunities through the 33 high quality undervalued stocks.
• If stability matters more than excitement, focus on lower risk profiles and stronger balance sheets using the 32 resilient stocks with low risk scores.
• When income is the priority, zero in on payout heavy businesses by scanning a focused set of 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com